176 related articles for article (PubMed ID: 34689796)
1. The acceptability of targeted mass treatment with primaquine for local elimination of vivax malaria in a northern Myanmar township: a mixed-methods study.
Aung PL; Soe MT; Soe TN; Oo TL; Aung PP; Khin A; Thi A; Phuanukoonnon S; Okanurak K; Cui L; Kyaw MP; Parker DM
Parasit Vectors; 2021 Oct; 14(1):549. PubMed ID: 34689796
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness, Safety, and Acceptability of Primaquine Mass Drug Administration in Low-Endemicity Areas in Southern Thailand: Proof-of-Concept Study.
Kaewkungwal J; Roobsoong W; Lawpoolsri S; Nguitragool W; Thammapalo S; Prikchoo P; Khamsiriwatchara A; Pawarana R; Jarujareet P; Parker DM; Sripoorote P; Kengganpanich M; Ngamjarus C; Sattabongkot J; Cui L
JMIR Public Health Surveill; 2024 Jun; 10():e51993. PubMed ID: 38922648
[TBL] [Abstract][Full Text] [Related]
3. Interventions for promoting patients' adherence to 14-day primaquine treatment in a highly malaria-endemic township in Myanmar: a qualitative study among key stakeholders.
Win KM; Aung PL; Ring Z; Linn NYY; Kyaw MP; Nguitragool W; Cui L; Sattabongkot J; Lawpoolsri S
Malar J; 2023 Oct; 22(1):302. PubMed ID: 37814267
[TBL] [Abstract][Full Text] [Related]
4. Community acceptability, participation, and adherence to mass drug administration with primaquine for Plasmodium vivax elimination in Southern Thailand: a mixed methods approach.
Saita S; Roobsoong W; Khammaneechan P; Sukchan P; Lawpoolsri S; Sattabongkot J; Cui L; Okanurak K; Phuanukoonnon S; Parker DM
Malar J; 2023 Jan; 22(1):17. PubMed ID: 36635642
[TBL] [Abstract][Full Text] [Related]
5. Factors hindering coverage of targeted mass treatment with primaquine in a malarious township of northern Myanmar in 2019-2020.
Aung PL; Soe MT; Soe TN; Oo TL; Win KM; Cui L; Kyaw MP; Sattabongkot J; Okanurak K; Parker DM
Sci Rep; 2023 Apr; 13(1):5963. PubMed ID: 37045879
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of an Unsupervised Primaquine Regimen for Preventing Plasmodium vivax Malaria Relapses in Northeast Myanmar: A Single-Arm Nonrandomized Observational Study.
Malla P; Wang Z; Brashear A; Yang Z; Lo E; Baird K; Wang C; Cui L
J Infect Dis; 2024 May; 229(5):1557-1564. PubMed ID: 38041857
[TBL] [Abstract][Full Text] [Related]
7. Mass drug administrations with dihydroartemisinin-piperaquine and single low dose primaquine to eliminate Plasmodium falciparum have only a transient impact on Plasmodium vivax: Findings from randomised controlled trials.
Phommasone K; van Leth F; Peto TJ; Landier J; Nguyen TN; Tripura R; Pongvongsa T; Lwin KM; Kajeechiwa L; Thwin MM; Parker DM; Wiladphaingern J; Nosten S; Proux S; Nguon C; Davoeung C; Rekol H; Adhikari B; Promnarate C; Chotivanich K; Hanboonkunupakarn B; Jittmala P; Cheah PY; Dhorda M; Imwong M; Mukaka M; Peerawaranun P; Pukrittayakamee S; Newton PN; Thwaites GE; Day NPJ; Mayxay M; Hien TT; Nosten FH; Cobelens F; Dondorp AM; White NJ; von Seidlein L
PLoS One; 2020; 15(2):e0228190. PubMed ID: 32023293
[TBL] [Abstract][Full Text] [Related]
8. Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study.
Douglas NM; Poespoprodjo JR; Patriani D; Malloy MJ; Kenangalem E; Sugiarto P; Simpson JA; Soenarto Y; Anstey NM; Price RN
PLoS Med; 2017 Aug; 14(8):e1002379. PubMed ID: 28850568
[TBL] [Abstract][Full Text] [Related]
9. The acceptability of mass administrations of anti-malarial drugs as part of targeted malaria elimination in villages along the Thai-Myanmar border.
Kajeechiwa L; Thwin MM; Shee PW; Yee NL; Elvina E; Peapah P; Kyawt K; Oo PT; PoWah W; Min JR; Wiladphaingern J; von Seidlein L; Nosten S; Nosten F
Malar J; 2016 Sep; 15(1):494. PubMed ID: 27677694
[TBL] [Abstract][Full Text] [Related]
10. Association of Impaired Cytochrome P450 2D6 Activity Genotype and Phenotype With Therapeutic Efficacy of Primaquine Treatment for Latent Plasmodium vivax Malaria.
Baird JK; Louisa M; Noviyanti R; Ekawati L; Elyazar I; Subekti D; Chand K; Gayatri A; Instiaty ; Soebianto S; Crenna-Darusallam C; Djoko D; Hasto BD; Meriyenes D; Wesche D; Nelwan EJ; Sutanto I; Sudoyo H; Setiabudy R
JAMA Netw Open; 2018 Aug; 1(4):e181449. PubMed ID: 30646129
[TBL] [Abstract][Full Text] [Related]
11. Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax.
Milligan R; Daher A; Villanueva G; Bergman H; Graves PM
Cochrane Database Syst Rev; 2020 Aug; 8():CD012656. PubMed ID: 32816320
[TBL] [Abstract][Full Text] [Related]
12. Resolving the cause of recurrent Plasmodium vivax malaria probabilistically.
Taylor AR; Watson JA; Chu CS; Puaprasert K; Duanguppama J; Day NPJ; Nosten F; Neafsey DE; Buckee CO; Imwong M; White NJ
Nat Commun; 2019 Dec; 10(1):5595. PubMed ID: 31811128
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of primaquine regimens for primaquine-resistant Plasmodium vivax malaria in Thailand.
Wilairatana P; Silachamroon U; Krudsood S; Singhasivanon P; Treeprasertsuk S; Bussaratid V; Phumratanaprapin W; Srivilirit S; Looareesuwan S
Am J Trop Med Hyg; 1999 Dec; 61(6):973-7. PubMed ID: 10674681
[TBL] [Abstract][Full Text] [Related]
14. Novel Insights into Plasmodium vivax Therapeutic Failure: CYP2D6 Activity and Time of Exposure to Malaria Modulate the Risk of Recurrence.
Silvino ACR; Kano FS; Costa MA; Fontes CJF; Soares IS; de Brito CFA; Carvalho LH; Sousa TN
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32122891
[No Abstract] [Full Text] [Related]
15. Primaquine treatment for Plasmodium vivax--an essential tool for malaria control and elimination in Papua New Guinea.
Betuela I; Robinson LJ; Hetzel MW; Laman M; Siba PM; Bassat Q; Mueller I
P N G Med J; 2014; 57(1-4):68-74. PubMed ID: 26930890
[TBL] [Abstract][Full Text] [Related]
16. [Role of primaquine in malaria control and elimination in French-speaking Africa].
Briolant S; Pradines B; Basco LK
Bull Soc Pathol Exot; 2017 Aug; 110(3):198-206. PubMed ID: 28417346
[TBL] [Abstract][Full Text] [Related]
17. Haemolysis in G6PD Heterozygous Females Treated with Primaquine for Plasmodium vivax Malaria: A Nested Cohort in a Trial of Radical Curative Regimens.
Chu CS; Bancone G; Moore KA; Win HH; Thitipanawan N; Po C; Chowwiwat N; Raksapraidee R; Wilairisak P; Phyo AP; Keereecharoen L; Proux S; Charunwatthana P; Nosten F; White NJ
PLoS Med; 2017 Feb; 14(2):e1002224. PubMed ID: 28170391
[TBL] [Abstract][Full Text] [Related]
18. Interventions for promoting patients' adherence to 14-day primaquine treatment in a highly malaria-endemic township in Myanmar: A qualitative study among key stakeholders.
Win KM; Aung PL; Ring Z; Linn NYY; Kyaw MP; Nguitragool W; Cui L; Sattabongkot J; Lawpoolsri S
Res Sq; 2023 Sep; ():. PubMed ID: 37720045
[TBL] [Abstract][Full Text] [Related]
19. Monitoring the Efficacy of Chloroquine-Primaquine Therapy for Uncomplicated Plasmodium vivax Malaria in the Main Transmission Hot Spot of Brazil.
Ladeia-Andrade S; Menezes MJ; de Sousa TN; Silvino ACR; de Carvalho JF; Salla LC; Nery OA; de Melo GNP; Corder RM; Rodrigues PT; Ferreira MU
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30782991
[TBL] [Abstract][Full Text] [Related]
20. A pilot randomized controlled trial to compare the effectiveness of two 14-day primaquine regimens for the radical cure of vivax malaria in South India.
Saravu K; Tellapragada C; Kulavalli S; Xavier W; Umakanth S; Brahmarouphu G; Srinivas NK; Channabasavaiah JP; Bava A; Saadi AV; Guddattu V; Satyamoorthy K; Bhat K
Malar J; 2018 Sep; 17(1):321. PubMed ID: 30176897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
